NT_1170x120_1-11-18

acute treatment of migraine

Dr. Reddy’s gets FDA approval for Tosymra

Dr. Reddy’s gets FDA approval for Tosymra

PRINCETON, N.J. — Dr. Reddy’s Laboratories and its subsidiary, Promius Pharma. today announced the approval of Tosymra (previously known as DFN-02) by the U.S. Food and Drug Administration (FDA). Tosymra is indicated for the acute treatment of migraine with or without aura in adults. Tosymra is the latest product to join the Promius Pharma acute migraine treatment

Eli Lilly to acquire CoLucid for $960 million

Eli Lilly to acquire CoLucid for $960 million

INDIANAPOLIS — Eli Lilly and Co. plans to buy CoLucid Pharmaceuticals Inc., maker of a promising migraine medication, for about $960 million in cash. Cambridge, Mass.-based CoLucid is currently in development with lasmiditan tablets, indicated for acute treatment of migraine, and has completed the first of two Phase 3 trials. A data read-out for the